Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics NASDAQ:CTNM said on Monday an experimental depression drug it developed with Johnson & Johnson NYSE:JNJ failed to meet the main goal of a mid-stage study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.